Investigating neurophysiological markers in different types of schizophrenia
Investigation of Clinical, Cognitive and Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NA · University Hospital, Strasbourg, France · NCT03649581
This study is trying to find out if different types of schizophrenia have unique brain patterns and symptoms to help create more personalized treatments for those affected.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT03649581 on ClinicalTrials.gov |
What this trial studies
This study aims to identify and validate distinct subforms of psychotic disorders, specifically schizophrenia, which may have different clinical expressions and underlying causes. By utilizing clinical assessments, cognitive evaluations, and neurophysiological measures such as fMRI, the research will compare two clinically distinguished subforms of schizophrenia that have not yet been scientifically validated. The goal is to better understand the physiopathological differences between these subforms to facilitate personalized treatment approaches.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with schizophrenia or schizo-affective disorder who are clinically stable and willing to participate.
Not a fit: Patients with severe or unstable somatic illnesses, neurological histories, or current substance use disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more precise diagnoses and tailored treatments for individuals with schizophrenia.
How similar studies have performed: While the approach of identifying subforms of psychotic disorders is not widely tested, similar studies have shown promise in refining diagnoses and treatments in psychiatric conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * for both patients and controls * male or female willing to participate and who have signed up the legal document * under the protection of health insurance for patients only * schizophrenia or schizo-affective disorder according to the DSM-5 criteria * periodic catatonia or hebephrenia accordin to WKL classification * clinically stable for at least 2 months * in or out patients for controls only * no psychiatric history Exclusion Criteria: * for both patients and controls * current severe or unstable somatic illness * neurological history (epilepsia, brain injury, brain surgery…) * current substance use disorder (DSM-5) * current major depressive disorder (DSM-5) * mental retardation (IQ \< 70) * pregnancy, breast feeding * current legal control * contra-indication for fMRI for controls only psychotropic intake during the last 3 weeks
Where this trial is running
Strasbourg
- Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Fabrice BERNA, MD
- Email: fabrice.berna@chru-strasbourg.fr
- Phone: 03 88 11 64 62
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenia